In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

BACKGROUND: Small cell lung cancer (SCLC) is the most aggressive lung tumor, characterized by a rapid doubling time and the development of widespread metastases, for which immune checkpoint inhibitors have been approved to overcome T cell anergy. In light of its dismal prognosis, and lack of curativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yusuke, Oronsky, Bryan, Abrouk, Nacer, Cabrales, Pedro, Reid, Tony R., Lee, Min-Jung, Yuno, Akira, Baker, Jonathan, Lee, Sunmin, Trepel, Jane B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867783/
https://www.ncbi.nlm.nih.gov/pubmed/33569311
http://dx.doi.org/10.21037/tlcr-20-359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867783/
https://www.ncbi.nlm.nih.gov/pubmed/33569311
http://dx.doi.org/10.21037/tlcr-20-359

Ejemplares similares